Regulus Therapeutics (NASDAQ:RGLS) Posts Quarterly Earnings Results, Hits Estimates

Regulus Therapeutics (NASDAQ:RGLS) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20), Zacks reports. During the same period last year, the company posted ($0.40) earnings per share.

Regulus Therapeutics Price Performance

Shares of RGLS stock opened at $1.36 on Friday. The business’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.45. Regulus Therapeutics has a one year low of $0.83 and a one year high of $3.00. The stock has a market capitalization of $89.08 million, a PE ratio of -1.27 and a beta of 1.42.

Wall Street Analyst Weigh In

RGLS has been the subject of several recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Regulus Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Friday, March 14th.

Insider Activity at Regulus Therapeutics

In other Regulus Therapeutics news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the transaction, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Joseph P. Hagan purchased 50,000 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were acquired at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 260,808 shares in the company, valued at approximately $284,280.72. This represents a 23.72 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 223,998 shares of company stock worth $282,237 over the last ninety days. Insiders own 4.35% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.